Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China
· Delayed Price · Currency is CNY 32.81
-0.91 (-2.70%)
Mar 9, 2026, 3:00 PM CST
SHA:688076 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,943 | 1,623 | 1,033 | 648.03 | 641.71 | Upgrade
|
| Other Revenue | - | 1.99 | 0.82 | 3.26 | 2.16 | Upgrade
|
| Revenue | 1,943 | 1,625 | 1,034 | 651.29 | 643.87 | Upgrade
|
| Revenue Growth (YoY) | 19.57% | 57.21% | 58.69% | 1.15% | 13.58% | Upgrade
|
| Cost of Revenue | - | 575.05 | 444.27 | 307.94 | 306.3 | Upgrade
|
| Gross Profit | 1,943 | 1,050 | 589.28 | 343.36 | 337.57 | Upgrade
|
| Selling, General & Admin | - | 339.13 | 268.23 | 186.98 | 150.49 | Upgrade
|
| Research & Development | - | 227.45 | 124.89 | 69.47 | 63.09 | Upgrade
|
| Other Operating Expenses | 1,543 | 1.7 | 0.02 | 9.25 | 5.24 | Upgrade
|
| Operating Expenses | 1,543 | 588.89 | 398.25 | 271.58 | 220.47 | Upgrade
|
| Operating Income | 400.05 | 460.86 | 191.04 | 71.78 | 117.1 | Upgrade
|
| Interest Expense | - | -34.75 | -16.09 | -9.26 | -6.12 | Upgrade
|
| Interest & Investment Income | - | 9.05 | 9.11 | 28.54 | 8.38 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 8.68 | -1.38 | 1.03 | -1.58 | Upgrade
|
| Other Non Operating Income (Expenses) | -48.15 | -0.58 | -0.47 | -0.3 | -0 | Upgrade
|
| EBT Excluding Unusual Items | 351.9 | 443.26 | 182.22 | 91.79 | 117.78 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -1.28 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -2.79 | 0.26 | -1.96 | 0.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -9.2 | -15.06 | 18.44 | -0.97 | Upgrade
|
| Other Unusual Items | - | 7.24 | 5.71 | 14.9 | 10.07 | Upgrade
|
| Pretax Income | 351.9 | 438.5 | 173.13 | 123.16 | 125.73 | Upgrade
|
| Income Tax Expense | 24.9 | 38.69 | 7.67 | 0.39 | 16.92 | Upgrade
|
| Earnings From Continuing Operations | 327 | 399.82 | 165.45 | 122.77 | 108.81 | Upgrade
|
| Minority Interest in Earnings | - | 4.57 | -2.52 | 6.34 | 6.58 | Upgrade
|
| Net Income | 327 | 404.39 | 162.94 | 129.11 | 115.39 | Upgrade
|
| Net Income to Common | 327 | 404.39 | 162.94 | 129.11 | 115.39 | Upgrade
|
| Net Income Growth | -19.14% | 148.19% | 26.20% | 11.89% | -6.52% | Upgrade
|
| Shares Outstanding (Basic) | 314 | 301 | 300 | 296 | 269 | Upgrade
|
| Shares Outstanding (Diluted) | 314 | 308 | 300 | 296 | 269 | Upgrade
|
| Shares Change (YoY) | 2.19% | 2.52% | 1.28% | 10.06% | 19.95% | Upgrade
|
| EPS (Basic) | 1.04 | 1.34 | 0.54 | 0.44 | 0.43 | Upgrade
|
| EPS (Diluted) | 1.04 | 1.31 | 0.54 | 0.44 | 0.43 | Upgrade
|
| EPS Growth | -20.87% | 142.09% | 24.60% | 1.66% | -22.07% | Upgrade
|
| Free Cash Flow | - | -690.01 | -310.43 | -409.07 | -52.61 | Upgrade
|
| Free Cash Flow Per Share | - | -2.24 | -1.03 | -1.38 | -0.20 | Upgrade
|
| Dividend Per Share | - | 0.643 | 0.286 | 0.143 | 0.107 | Upgrade
|
| Dividend Growth | - | 125.03% | 99.93% | 33.43% | - | Upgrade
|
| Gross Margin | 100.00% | 64.61% | 57.02% | 52.72% | 52.43% | Upgrade
|
| Operating Margin | 20.59% | 28.36% | 18.48% | 11.02% | 18.19% | Upgrade
|
| Profit Margin | 16.83% | 24.89% | 15.77% | 19.82% | 17.92% | Upgrade
|
| Free Cash Flow Margin | - | -42.47% | -30.04% | -62.81% | -8.17% | Upgrade
|
| EBITDA | 601.93 | 662.75 | 322.81 | 170.52 | 198.73 | Upgrade
|
| EBITDA Margin | 30.98% | 40.79% | 31.23% | 26.18% | 30.87% | Upgrade
|
| D&A For EBITDA | 201.88 | 201.88 | 131.77 | 98.75 | 81.63 | Upgrade
|
| EBIT | 400.05 | 460.86 | 191.04 | 71.78 | 117.1 | Upgrade
|
| EBIT Margin | 20.59% | 28.36% | 18.48% | 11.02% | 18.19% | Upgrade
|
| Effective Tax Rate | 7.08% | 8.82% | 4.43% | 0.32% | 13.46% | Upgrade
|
| Revenue as Reported | - | 1,625 | 1,034 | 651.29 | 643.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.